Literature DB >> 10231840

Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats.

Y Yamaguchi1, F Matsumura, J Liang, K Okabe, T Matsuda, H Ohshiro, K Ishihara, E Akizuki, S Yamada, M Ogawa.   

Abstract

We investigated the role of platelet-activating factor (PAF) as a priming signal for cytokine-induced neutrophil chemoattractant (CINC) expression by bronchoalveolar macrophages in acute pancreatitis. Pancreatitis was induced by four intramuscular injections of cerulein (50 micrograms/kg at 1-h intervals) in Wistar rats. The animals were injected intraperitoneally with 10 micrograms/kg of lipopolysaccharide (LPS) as a septic challenge. Pancreatitis rats were treated with a bolus intravenous injection of TCV-309 (3 or 30 micrograms/kg) 30 min before the septic challenge. Intense mononuclear cell infiltration and lung hemorrhage occurred in pancreatitis rats complicated with sepsis but were not seen in pancreatitis rats receiving a bolus TCV-309. Pancreatitis rats treated with TCV-309 had lower serum concentrations of CINC after septic challenge and lower levels of CINC messenger RNA (mRNA) in the lung, as well as fewer pulmonary infiltrates immunoreactive for CINC or Mac-1 (CD11b/CD18). In vitro CINC production in response to LPS by bronchoalveolar macrophages obtained from pancreatitis rats 6 h after the first cerulein injection, immediately before septic challenge, was enhanced but was significantly reduced in a TCV-309-sensitive manner. LPS-stimulated in vitro CINC production by naive bronchoalveolar macrophages was significantly enhanced by pretreatment with PAF. TMB-8 (an inhibitor of calcium release from endoplasmic reticulum) or W7 (calmodulin antagonist) completely abrogated the chemoattractant production by bronchoalveolar macrophages pretreated with PAF after LPS stimulation. Altered intracellular calcium, due to Ca2+ efflux from intracellular stores, may be involved in the "priming" of bronchoalveolar macrophages to release CINC after triggering with LPS during acute cerulein-induced pancreatitis. The PAF antagonist TCV-309 effectively prevented hyperactivity of bronchoalveolar macrophages and pancreatitis-associated lung injury after the septic challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231840     DOI: 10.1097/00006676-199905000-00005

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Involvement of apoptosis of alveolar epithelial cells in acute pancreatitis-associated lung injury.

Authors:  Yao-Zong Yuan; Zi-Hua Gong; Kai-Xian Lou; Shui-Ping Tu; Zu-Kang Zhai; Jia-Yu Xu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Study progress in therapeutic effects of traditional Chinese medicine monomer in severe acute pancreatitis.

Authors:  Xi-ping Zhang; Da-ren Liu; Yan Shi
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

Review 3.  Essential role of monocytes and macrophages in the progression of acute pancreatitis.

Authors:  Pratima Shrivastava; Madhav Bhatia
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 4.  Role of platelet-activating factor in the pathogenesis of acute pancreatitis.

Authors:  Li-Rong Liu; Shi-Hai Xia
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

5.  The role of the intestine in the pathophysiology and management of severe acute pancreatitis.

Authors:  R S Flint; J A Windsor
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 6.  Therapy for acute pancreatitis with platelet-activating factor receptor antagonists.

Authors:  Chong Chen; Shi-Hai Xia; Hong Chen; Xiao-Hong Li
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

7.  Role of platelet-activating factor in acid-induced esophageal mucosal injury.

Authors:  W G Paterson; C A Kieffer; M J Feldman; D V Miller; G P Morris
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.